[S-12]

Chemoprevention of Colon Cancer

Keiji Wakabayashi, Ph.D.
National Cancer Center Research Institute, Japan.

Colon cancer is one of the most common malignancies in humans, and the search for effective chemopreventive agents is an important and urgent task. Expression levels of inflammation-related enzymes, cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) are elevated in colon cancers, and their products, prostaglandins and nitric oxide, are suggested to be involved in colon carcinogenesis. Thus, inhibition of COX and NOS activity is thought to be an appropriate approach for chemoprevention.

Clear suppressive effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on colon cancer development have been reported and considered attributable to inhibition of COX, both constitutive COX-1 and inducible COX-2 forms, being involved in a resultant decrease in PGE₂ production. Genetic and pharmacological approaches have revealed that PGE₂ is responsible for colon carcinogenesis through its binding to PGE₂ receptor subtypes EP₁, EP₂ and EP₄. Based on these observations, we have demonstrated that COX-1 or COX-2 selective inhibitors, and EP₁- or EP₄- selective antagonists are good candidate chemopreventive agents against colon cancer in animal experiments. In addition to COX inhibitors and PGE₂ receptor antagonists, the NOS inhibitors, L-NAME and ONO-1714 could be shown to also reduce azoxymethane-induced colonic aberrant crypt foci formation in rats. The way forward in the identification of new and safer chemopreventive agents for colon cancer will be discussed.